MANAGEMENT OF TTP – THE MAIN OPTIONS FOR DIAGNOSIS
DOI:
https://doi.org/10.5281/zenodo.8014901Keywords:
TTP, ADAMTS13, assay, activity, antigen, antibodyAbstract
Thrombotic thrombocytopenic purpura (TTP) is a thrombotic microangiopathy caused by severe deficiency of ADAMTS13, a von Willebrand factor (VWF)-specific protease.1 TTP is a severe condition and a medical emergency in hematology. Prolonged time from presentation to diagnosis and therapeutic actions is life-threatening. Establishing a clear diagnosis of TTP is essential, as the therapeutic measures for TTP may include invasive procedures that have risks of their own.1
Therefore, the discovering and production of a synthetic ADAMTS13-specific VWF fragment (VWF73) allowed for quantification of ADAMTS13 activity, the basis for TTP diagnosis. Further advances led to the development of faster and reliable technologies2 One of these widely used methods is fluorescence resonance energy transfer (FRET).
Recently, several rapid ADAMTS13 activity assays have become available to potentially fill this void. One is a semi-quantitative screening assay from Technoclone3, and the other is a fully automated, quantitative chemiluminescence-based immunoassay (CLIA; HemosIL AcuStar ADAMTS13 Activity, Instrumentation Laboratory, Bedford, MA).4
The ELISA based activity assay, manufactured by Technoclone (Vienna, Austria) and named Technozym ADAMTS-13 Activity, is the most widely used according to ECAT data.5 The ELISA based Antigen assay is also possible.5
Further advances in diagnostic methods led to identifying immune-mediated TTP (iTTP) via the presence of anti-ADAMTS13 immunoglobulin G (IgG) autoantibodies. Methodologies used include enzyme-linked immunosorbent assays (ELISAs) and/or functional inhibitor assays based on mixing studies.6 The most common approach here is the assessment for functional inhibitors (ie, autoantibodies that block ADAMTS13 activity) using a Bethesda-like assay.7
References
Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood 2017;129:2836–46.
Kokame K, Matsumoto M, Fujimura Y, Miyata T. VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13. Blood 2004;103:607–12
Moore GW, Meijer D, Griffiths M, et al. A multi-center evaluation of TECHNOSCREEN® ADAMTS-13 activity assay as a screening tool for detecting deficiency of ADAMTS-13. J Thromb Haemost. 2020;18 (7):1686-1694.
Favaloro EJ, Mohammed S, Chapman K, et al. A multicentre laboratory assessment of a new automated chemiluminescent assay for ADAMTS13 activity. J Thromb Haemost. 2021;19(2):417-428.
Favaloro EJ, Pasalic L, Henry B, Lippi G. Laboratory testing for ADAMTS13: Utility for TTP diagnosis/exclusion and beyond. Am J Hematol. 2021 Aug 1;96(8):1049-1055. doi: 10.1002/ajh.26241. Epub 2021 May 31. PMID: 33991361.
Vendramin C, Thomas M, Westwood JP, Scully M. Bethesda Assay for Detecting Inhibitory Anti-ADAMTS13 Antibodies in Immune-Mediated Thrombotic Thrombocytopenic Purpura. TH Open. 2018 Sep 26;2(3):e329-e333. doi: 10.1055/s-0038-1672187. PMID: 31249957; PMCID: PMC6524890.
Alwan F, Vendramin C, Vanhoorelbeke K, et al. Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura. Blood 2017;130(04):466–471
Laboratory Corporation of America. Directory of Services and Interpretive Guide. ADAMTS13 Activity Reflex Profile. www.labcorp.com. 2016. Ref Type: Internet Communication
Hoffbrand V, Moss P, Hoffbrand’s Essential Haematology, ed. 7, Wilwy Blackwell, 2016
Saifan C, Nasr R, Mehta S, Acharya PS, El-Sayegh S. Thrombotic Thrombocytopenic Purpura. In J Blood Disord Transfus, 2012, S3:001. doi:10.4172/2155-9864.S3-001.
South K.,Luken, B.M.,Crawley JTB.,Phillis R, Thomas M, Collins,R.,Deforche L, Vanhoorelbeke K and Lane DA. Conformational activation of ADAMTS 13. In PNAS 2014,vol.111,no.52,18578-18583, http://www.pnas.org/content/111/52/18578.full.
Tsai HM”Thrombotic Thrombocytopenic Purpura,Hemolytic-Uremic Syndrome,and Related Disorders” In Wintrobe’s Clinical Hematology, Greer J, Foerster J, Lukens J, Rodgers G, Pareskevas F, Glader B, Arber D, Means R.jr ,12th ed, Lippincott Williams & Wilkins, 2009, 1314-1325
Ai J, Smith P,Wang S, Zhang P. and Zheng XL. The Proximal Carboxyl-terminal Domains of ADAMTS-13 Determine Substrat Specificity and Are All Required for Cleavage of von Willebrand Factor. In J.Biol.Chem. 2005,280, 29428-29434.
Kremer Hovinga JA and Lämmle B. Role of ADAMTS13 in the pathogenesis,diagnosis,and treatment of thrombotic thrombocytopenic purpura. In ASH Education Book, 2012 vol. 2012 no. 1. 610-616. http://asheducationbook.hematologylibrary.org/content/2012/1/610.full.pdf+html
Scully M, Hunt BJ,Benjamin S, Liesner R, Rose P, Peyvandi F, Cheung B, Machin SJ. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. In British Journal of Haematology,2012, 158(3):323-35
Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005;129:93–100.
Dimopoulos K, Philips M, Goetze JP. Diagnosis of Thrombotic Thrombocytopenic Purpura by ADAMTS13 Activity Quantification. J Appl Lab Med. 2022 May 4;7(3):637-649. doi: 10.1093/jalm/jfab148. PMID: 34977929.
Mirabet M, Blanch S. Josep Puig JS. Highly sensitive fully automated chemiluminescent immunoassay for rapid quantification of ADAMTS13 activity. XXVI Congress International Society Thrombosis Haemostasis 63rd Annual Scientific Standardization Committee Meeting. 2017: PB 703. doi:10.3252/pso.eu.ISTH2017
https://www.technoclone.com/en/product/adamts13-chromogenic-elisas
Laborator Synevo. Referințele specifice tehnologiei de lucru utilizate, 2016. Ref Type: Catalog
https://www.technoclone.com/en/product/adamts13-screening-assay
Mayo Clinic, Mayo Medical Laboratories. Reference Laboratory Services for Health Care Organizations. ADAMTS13 Activity and Inhibitor Profile. www.mayomedicallaboratories.com. 2016. Ref Type: Internet Communication.
Starke R, Machin S, Scully M, Purdy G, Mackie I. The clinical utility of ADAMTS13 activity, antigen and autoantibody assays in thrombotic thrombocytopenic purpura. Br J Haematol. 2007 Feb;136(4):649-55. doi: 10.1111/j.1365-2141.2006.06471.x. PMID: 17367414.
Rieger M, Mannucci PM, Kremer Hovinga JA, et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood 2005;106(04):1262–1267
Tsai H-M, Raoufi M, Zhou W, et al. ADAMTS13-binding IgG are present in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 2006;95(05):886–892
Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998;339(22):1585–1594
Peyvandi F, Ferrari S, Lavoretano S, Canciani MT, Mannucci PM. Von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura. Br J Haematol 2004;127(04):433–439
Klaus C, Plaimauer B, Studt J-D, et al. Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood 2004;103(12):4514–4519
Scheiflinger F, Knöbl P, Trattner B, et al. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood 2003;102(09):3241–3243
Kasper CK, Aledort L, Aronson D, et al. Proceedings: a more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975;34(02):612
Verbruggen B, Novakova I,Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995;73(02):247–251
ScullyM, Cohen H, Cavenagh J, et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol 2007;136(03):451–461
Mancini I, Valsecchi C, Palla R, Lotta LA, Peyvandi F.Measurement of anti-ADAMTS13 neutralizing autoantibodies: a comparison between CBA and FRET assays. J Thromb Haemost 2012;10(07):1439–1442
Downloads
Published
How to Cite
License
Copyright (c) 2023 Roxana Cătălina Ferea, Stejara Nicoleta Mihai, Cristina Tatiana Enache
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
